A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures
NCT ID: NCT00367432
Last Updated: 2020-11-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
398 participants
INTERVENTIONAL
2006-07-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Levetiracetam
Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
Levetiracetam
Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levetiracetam
Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Japan Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aichi-gun, Aichi-ken, Japan
Nagoya, Aichi-ken, Japan
Hirosaki, Aomori, Japan
Matsudo, Chiba, Japan
Kitakyushu, Fukuoka, Japan
Koga, Fukuoka, Japan
Kurume, Fukuoka, Japan
Fukuyama, Hiroshima, Japan
Asahikawa, Hokkaido, Japan
Hakodate, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Kobe, Hyōgo, Japan
Kahoku-gun, Ishikawa-ken, Japan
Kanazawa, Ishikawa-ken, Japan
Zentsujichó, Kagawa-ken, Japan
Kōshi, Kumamoto, Japan
Tsu, Mie-ken, Japan
Iwanuma, Miyagi, Japan
Sendai, Miyagi, Japan
Ōmura, Nagasaki, Japan
Kashihara, Nara, Japan
Nagaoka, Niigata, Japan
Beppu, Oita Prefecture, Japan
Izumi, Osaka, Japan
Neyagawa, Osaka, Japan
Suita, Osaka, Japan
Takatsuki, Osaka, Japan
Iruma-gun, Saitama, Japan
Shimotsuga-gun, Tochigi, Japan
Shimotsuke, Tochigi, Japan
Komatsushimachō, Tokushima, Japan
Chiyoda-Ku, Tokyo, Japan
Kodaira, Tokyo, Japan
Kokubunji, Tokyo, Japan
Shinjuku-ku, Tokyo, Japan
Taito-ku, Tokyo, Japan
Ube, Yamaguchi, Japan
Aomori, , Japan
Chiba, , Japan
Fukuoka, , Japan
Fukushima, , Japan
Gifu, , Japan
Hiroshima, , Japan
Kagoshima, , Japan
Kumamoto, , Japan
Kyoto, , Japan
Miyazaki, , Japan
Niigata, , Japan
Okayama, , Japan
Osaka, , Japan
Shizuoka, , Japan
Toyama, , Japan
Yamagata, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-004334-26
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
N01222
Identifier Type: -
Identifier Source: org_study_id